Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML)

Silke Kapp-Schwoerer, MD, Sibylle Cocciardi, Jan Kroenke, MD, Anna Dolnik, PhD, Tamara J. Blätte, Andrea Corbacioglu, PhD, Verena I. Gaidzik, MD, Peter Paschka, MD, Maria-Veronica Teleanu, MD, Karlheinz Holzmann, PhD, Gudrun Göhring, MD, Felicitas Thol, MD, Michael Heuser, MD, Arnold Ganser, MD PhD, Richard F. Schlenk, MD, Hartmut Döhner, Prof. Dr., Lars Bullinger, MD, Konstanze Döhner, MD

Blood (2015) 126 (23): 1381.

https://doi.org/10.1182/blood.V126.23.1381.1381

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1 , FLT3 -ITD, and CEBPA : A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT

Blood (2014) 124 (21): 324.

https://doi.org/10.1182/blood.V124.21.324.324

Published: 2014

Journal Articles

No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma

Mathias J Rummel, MD, PhD, Aline Tenzer, Norbert Niederle, MD, PhD, Chrisoph Losem, MD, PhD, Christina Balser, MD, PhD, Harald-E. Balló, MD, PhD, Manfred Welslau, MD, PhD, Ulrich von Grünhagen, MD, PhD, Wolfram Brugger, MD, PhD, Georg Maschmeyer, MD, PhD, Axel C. Matzdorff, MD, PhD, Arnold Ganser, MD, PhD, Eckhart Weidmann, MD, PhD, Gerhard Heil, MD, PhD, Axel Hinke, Jürgen Barth

Blood (2010) 116 (21): 3090.

https://doi.org/10.1182/blood.V116.21.3090.3090

Published: 2010

Journal Articles

Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia.

Blood (2009) 114 (22): 2960.

https://doi.org/10.1182/blood.V114.22.2960.2960

Published: 2009

Journal Articles

Lineage-Specific Regulation of miRNA-Expression by the BCR-ABL Oncogene.

Michaela Scherr, PhD, Letizia Venturini, PhD, Karin Battmer, Arnold Ganser, MD, PhD, Matthias Eder, MD

Blood (2008) 112 (11): 1084.

https://doi.org/10.1182/blood.V112.11.1084.1084

Published: 2008

Journal Articles

Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Christian Koenecke, MD, Philipp Kümpers, MD, Alexander Lukasz, Hartmut Hecker, MD, Elke Dammann, Willem Verhagen, MD, Sascha David, MD, Gudrun Göhring, MD, Stefanie Buchholz, MD, Eva Weissinger, MD, PhD, Jürgen Krauter, MD, Ph.D., Matthias Eder, MD, Ph.D., Hermann Haller, MD, Ph.D., Arnold Ganser, MD, PhD

Blood (2008) 112 (11): 3259.

https://doi.org/10.1182/blood.V112.11.3259.3259

Published: 2008

Journal Articles

Extramedullary Acute Leukemias prior to and after Allogeneic Hematopoietic Stem Cell Transplantation: a Single Center Study.

Michael Stadler, MD, PhD, Helmut Diedrich, MD, Elke Dammann, Stefanie Buchholz, MD, Eva Mischak-Weissinger, MD, PhD, Juergen Krauter, MD, PhD, Matthias Eder, MD, PhD, Arnold Ganser, MD, PhD

Blood (2008) 112 (11): 3262.

https://doi.org/10.1182/blood.V112.11.3262.3262

Published: 2008

Journal Articles

Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?

Christiane Dobbelstein, MD, Haytham Kamal, MD, Elke Dammann, Eva Mischak-Weissinger, MD, PhD, Michael Stadler, MD, PhD, Juergen Krauter, MD, PhD, Arnold Ganser, MD, PhD, Matthias Eder, MD, PhD

Blood (2008) 112 (11): 343.

https://doi.org/10.1182/blood.V112.11.343.343

Published: 2008

Journal Articles

Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies

Jürgen Krauter, Gerhard Heil, Dieter Hoelzer, MD, PhD, Hans Martin, Oliver G. Ottmann, Jürgen Finke, Michael Lübbert, MD, PhD, Wolfgang Heit, Walter Fiedler, Lothar Kanz, MD, Günter Schlimok, Hartmut Kirchner, Aruna Raghavachar, Wolfram Brugger, Hartmut Döhner, Arnold Ganser, MD, PhD

Blood (2008) 112 (11): 344.

https://doi.org/10.1182/blood.V112.11.344.344

Published: 2008

Journal Articles

Trans-Atlantic Consensus on the Medical Management of Radiation Accident Victims

Bhawna Sirohi, Raymond Powles, MD, Dietger Niederweiser, Norm Coleman, Nelson J. Chao, MD, Judith Bader, Cullen Case, Jr., John Chute, MD, Dennis L. Confer, MD, Patrick Gourmelon, Norbert C Gorin, Arnold Ganser, MD, PhD, Matthias Port, Viktor Meineke, Robert Krawisz, David M Weinstock, MD, Albert Wiley, MD, PhD, Ted Fliedner

Blood (2008) 112 (11): 2361.

https://doi.org/10.1182/blood.V112.11.2361.2361

Published: 2008

Journal Articles

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Kerstin Wittke, Annegret Becker, Andreas Zimmermann, Brigitte Schlegelberger, MD, Arnold Ganser, MD, PhD, Daniela Spaeth, Hartmut Doehner, MD, Konstanze Doehner, MD

Blood (2008) 112 (11): 145.

https://doi.org/10.1182/blood.V112.11.145.145

Published: 2008

Journal Articles

Potentiation of Topoisomerase II Inhibitor-Mediated Myeloid Leukemia Cell Kill by Farnesyltransferase Inhibitor L-744,832.

Fredrick O. Onono, MSc, Michael A. Morgan, PhD, Jeanny Wegner, MD, Arnold Ganser, MD/PhD, Christoph W.M. Reuter, MD/PhD

Blood (2007) 110 (11): 3479.

https://doi.org/10.1182/blood.V110.11.3479.3479

Published: 2007

Journal Articles

Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.

Nicola Gökbuget, MD, Renate Arnold, MD, PhD, Angelika Böhme, MD, PhD, Rainer Fietkau, MD, PhD, Mathias Freund, MD, PhD, Arnold Ganser, MD, PhD, Michael Kneba, MD, PhD, Thomas Lipp, MD, Wolf-Dieter Ludwig, MD, PhD, Georg Maschmeyer, MD, PhD, Dorle Messerer, Harald Rieder, MD, PhD, Eckard Thiel, MD, PhD, Dieter Hoelzer, MD, PhD

Blood (2007) 110 (11): 12.

https://doi.org/10.1182/blood.V110.11.12.12

Published: 2007

Journal Articles

Characterization of a Novel R-RAS Mutation Cloned from Primary AML Cells.

Christoph W.M. Reuter, MD, PhD, Erdem Aydilek, MD, Fredrick O. Onono, Michael A. Morgan, PhD, Kristine A. Henningfeld, PhD, Arnold Ganser, MD/PhD

Blood (2006) 108 (11): 1439.

https://doi.org/10.1182/blood.V108.11.1439.1439

Published: 2006

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients - A Single Center Study.

Michael Stadler, MD, PhD, Bernd Hertenstein, MD, PhD, Juergen Krauter, MD, PhD, Stefanie Buchholz, MD, Elke Dammann, Matthias Eder, MD, PhD, Arnold Ganser, MD, PhD

Blood (2006) 108 (11): 3030.

https://doi.org/10.1182/blood.V108.11.3030.3030

Published: 2006

Journal Articles

Atypical Presentations of EBV Reactivation and EBV-Associated PTLD Post-HSCT: Implication for Routine EBV Surveillance after Allogeneic HSCT?.

Christiane E. Dobbelstein, MD, Haytham M. Kamal, MD, Elke Dammann, Bernd Hertenstein, MD, PhD, Eva M. Weissinger, MD, PhD, Arnold Ganser, MD, PhD.

Blood (2005) 106 (11): 5364.

https://doi.org/10.1182/blood.V106.11.5364.5364

Published: 2005

Journal Articles

Prenylation Inhibitors Block IL-6 and IGF-1 Dependent Activation of RAS Signaling in Multiple Myeloma Cells.

Christoph W.M. Reuter, MD, PhD, Michael A. Morgan, PhD, Dietrich Peest, MD/PhD, Arnold Ganser, MD/PhD

Blood (2005) 106 (11): 3373.

https://doi.org/10.1182/blood.V106.11.3373.3373

Published: 2005

Journal Articles

Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.

Aristoteles A.N. Giagounidis, MD, Sabine Haase, Ulrich Germing, MD, PhD, Claudia Schoch, MD, PhD, Brigitte Schlegelberger, PhD, Ludwig Wilkens, PhD, Guntram Büsche, MD, Hans H. Kreipe, MD, PhD, Manuel Aivado, MD, Michael Lübbert, MD, PhD, Arnold Ganser, MD, PhD, Carlo Aul, MD, PhD

Blood (2004) 104 (11): 4729.

https://doi.org/10.1182/blood.V104.11.4729.4729

Published: 2004

NARROW

Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML)

No Elevated Rates of Treatment-Related Myelodysplastic Syndromes and Second Solid Tumors Following Therapy with Bendamustine Compared with Other Anti-Lymphoma Regimes for Low-Grade Non-Hodgkin's Lymphoma

Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia.

Lineage-Specific Regulation of miRNA-Expression by the BCR-ABL Oncogene.

Circulating Angiopoietin-2 Predicts Time to Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.

Extramedullary Acute Leukemias prior to and after Allogeneic Hematopoietic Stem Cell Transplantation: a Single Center Study.

Lower Relapse Incidence and Relapse Mortality in Patients Transplanted from a Younger Sibling in HLA-Identical Stem Cell Transplantation: Does Microchimerism Matter?

Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies

Trans-Atlantic Consensus on the Medical Management of Radiation Accident Victims

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

Potentiation of Topoisomerase II Inhibitor-Mediated Myeloid Leukemia Cell Kill by Farnesyltransferase Inhibitor L-744,832.

Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.

Characterization of a Novel R-RAS Mutation Cloned from Primary AML Cells.

Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients - A Single Center Study.

Atypical Presentations of EBV Reactivation and EBV-Associated PTLD Post-HSCT: Implication for Routine EBV Surveillance after Allogeneic HSCT?.

Prenylation Inhibitors Block IL-6 and IGF-1 Dependent Activation of RAS Signaling in Multiple Myeloma Cells.

Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only